By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...

The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics ...

New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug ...

Zymeworks is awaiting key regulatory decisions for zanidatamab, with potential EU and China approvals following. Read more ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Missak Haigentz, MD, highlights some of the significant unmet needs for patients with small cell lung cancer.

An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical ...

David Fajgenbaum, MD, MBA, MSc Sarcoma Foundation of America SFA's Vision of Hope Award will recognize physician-scientist David ...

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

Dr Victoria Kunene discusses a colorectal cancer vaccine trial and its revolutionary potential as part of the NHS Cancer ...

APP, MMYT, POWL, NVDA, and TGTX outperformed BTC's approximately 151% gain over the last year from September 27th, 2023, to ...